• Home Dutch
  •  EN 
  • Employee login

System biology approach for discovery of biomarkers of renal disease progressioni in diabetes (SysKid)

Print 

Title:  System biology approach for discovery of biomarkers of renal disease progressioni in diabetes (SysKid)
Investigator:   Michelle Pena 
Supervisor:  Hiddo Lambers Heerspink, 
Promotor:  Dick de Zeeuw 
Summary:  Approximately 40% of all chronic kidney diseases is of diabetic aetiology. Besides eventual progression towards end stage renal diseae, diabetic nephropathy impacts the patient quality of life including cardiovascular complications and bone metabolism disorders. The sysKID consortium aims to discover novel biomarkers for diabetic patients at risk for progression of renal disease. These biomarkers will provide the clinician with tools to evaluate the clinical evaluation for early stage diagnosis and prognosis and allows the clinical pharmacologist to assess individual therapy response and optimize personalized medicine. 
Financing:  sysKID Project (EU FP-7 project) 
Start:   1-02-2010 
End: 31-12-2014

Projects
The use of a multiple parameter response efficacy score to predict the effect of a drug on hard renal and cardiovascular
Diabetes Mellitus Treatment for Renal Insufficiency Consortium (DIAMETRIC) database 
System biology approach for discovery of biomarkers of renal disease progressioni in diabetes (SysKid)
PROVALID – prospective multinational cohort study in patients with type 2 diabetes treated in primary care
Vitamin-D deficiency as a risk marker for renal and CV complications in the general population
A novel approach of personalized medicine: considering multiple effects of a single drug
Optimal hard endpoints in clinical trials of renal disease progression
Albuminuria as surrogate endpoint in clinical trials
Individual therapy response to a sodium-glucose transport inhibitor
Involving patients in the assessment and evaluation of medication treatment
Groningen Initiative to Analyse Type-2 diabetes Treatment ( GIANTT )
The role of medication adherence in predicting treatment response and estimating cost-effectiveness of statin treatment
Pharmacogenetics and response to treatment of oral antidiabetics
Quality of prescribing: patient specific indicators that predict better outcomes in diabetes patients
Quality assessment of pharmacotherapy in patients with chronic kidney disease
Cost effectiveness of ACEi and ARBs on renal failure in diabetes patients
Drug information and risk communication in Africa
Regulatory Science Projects